menu
Vasomotor Symptoms of Menopause Market Size Forecast to Reach $893.15 Million by 2025
Vasomotor Symptoms of Menopause Market Size Forecast to Reach $893.15 Million by 2025
Hormonal Imbalance Which Leads to Premature Menopause Is Increasing the Growth of the Vasomotor Symptoms of Menopause Market.

The Vasomotor Symptoms of Menopause Market size is forecast to reach $893.15 million by 2025, growing at a CAGR of 6.51% during the forecast period 2020-2025. Vasomotor symptoms of menopause are the actions that are related to nerves and muscles that cause the blood vessels to dilate. Vasomotor symptoms of menopause are a transition between two phases: perimenopause and menopause. Hormonal imbalance which leads to premature menopause and increasing awareness of the vasomotor symptoms of menopause is the major factor driving the growth of the market. The rise in the number of companies investing in clinical trial candidates and increasing investments in research and development is set to further enhance the overall market demand for the Vasomotor Symptoms of Menopause Market during the forecast period 2020-2025.

Vasomotor Symptoms of Menopause Market Segment Analysis - By Therapy Type

The Hormonal segment held the largest share in the Vasomotor Symptoms of Menopause Market in 2019 and is estimated to grow at a CAGR of 7.13% during the forecast period 2020-2025 owing to the growing inclination of companies towards this therapy for the treatment and management of vasomotor symptoms. Estrogen is a hormone that plays various roles in the body. In females, it helps develop and maintain both the reproductive system and female characteristics, such as breasts and pubic hair. It contributes to cognitive health, bone health, the function of the cardiovascular system, and other essential bodily processes. However, most people know it for its role alongside progesterone in female sexual and reproductive health. Hormonal is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=16866

Report Price: $ 4500 (Single User License)

Vasomotor Symptoms of Menopause Market Segment Analysis - By Geography

North America dominated the Vasomotor Symptoms of Menopause Market in 2019 with a share of more than 43.17% followed by the Asia Pacific owing to the vast awareness towards novel treatments and more number of women actively seeking treatment-related menopause.

However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the initiatives taken by government bodies towards the overall health of women and the increasing medical tourism. Favourable healthcare policies are also increasing the growth of the Vasomotor Symptoms of Menopause Market in this region.

Vasomotor Symptoms of Menopause Market Drivers

Hormonal imbalance which leads to the premature menopause

Hormonal imbalance which leads to premature menopause is increasing the growth of the Vasomotor Symptoms of Menopause Market. As reproductive functions play out over time hormone levels take a plunge, triggering the onset of menopause and common hormone imbalances associated with the change of life. If stress takes center stage in our lives and becomes chronic, cortisol floods the system, and total hormone production lags. This forces the body to steal from its supplies of available progesterone, to make more cortisol, thus depleting this key balancing hormone with obvious implications for estrogen dominance. Prolonged stress tears up our bones, melts our muscles, robs us of strength and energy, lowers our libido, and overwhelms our immunities, putting us at serious risk for chronic illness and autoimmune disease. Thus, increasing the growth of the Vasomotor Symptoms of Menopause Market during the forecast period 2020-2025.

More number of women are actively seeking treatment related to menopause

More number of women are actively seeking treatment related to menopause is increasing the growth of the Vasomotor Symptoms of Menopause Market. To relieve vaginal dryness, estrogen can be administered directly to the vagina using a vaginal cream, tablet, or ring. This treatment releases just a small amount of estrogen, which is absorbed by the vaginal tissues. Certain antidepressants related to the class of drugs called selective serotonin reuptake inhibitors (SSRIs) can decrease menopausal hot flashes. Certain antidepressants related to the class of drugs called selective serotonin reuptake inhibitors (SSRIs) can decrease menopausal hot flashes. A low-dose antidepressant for the management of hot flashes can be useful for women who can't take estrogen for health reasons or for women who need an antidepressant for a mood disorder. Thus, increasing the growth of the Vasomotor Symptoms of Menopause Market during the forecast period 2020-2025.

Talk to one of our sales representative about the full report by providing your details in the link below:

https://www.industryarc.com/support.php?id=16866

Vasomotor Symptoms of Menopause Market Challenges

Side effects and disruption in the supply chain of drug


Some of the factors that is set to impede the growth of the Vasomotor Symptoms of Menopause Market are side effects and disruption in the supply chain of the drug.

Vasomotor Symptoms of Menopause Market Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the Vasomotor Symptoms of Menopause Market. In 2019, the Vasomotor Symptoms of Menopause Market share is consolidated by the top ten players present in the market. Vasomotor Symptoms of Menopause Market, the top 10 companies are Eli Lilly and Company, Procter & Gamble, Pfizer Inc., Ausio pharmaceuticals, LLC, EndoCeutics, Inc., Mithra Pharmaceuticals, Pfizer Inc., Novartis AG, Novo Nordisk A/S, Merck KGaA, Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd, and Edgemont Pharmaceuticals LLC among others.

Acquisitions/Product Launches

In April 2020, Mithra Pharmaceuticals, a Belgium-based company announced an update on the Donesta Phase III clinical program called “E4 Comfort”, which aims at enrolling approximately 2200 menopausal women (40-65 years).

Key Takeaways

North America dominated the Vasomotor Symptoms of Menopause Market in 2019 owing to the vast awareness towards novel treatment and more women are actively seeking treatment related to menopause. The Vasomotor Symptoms of Menopause Market scope for different regions will be provided in the final report.

Increasing incorporation of innovation in the industry and high investment in research and development is likely to aid in the market growth of the Vasomotor Symptoms of Menopause Market.

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Vasomotor Symptoms of Menopause Market report.

Side effects and disruption in the supply chain of the drug is poised to create hurdles for the Vasomotor Symptoms of Menopause Market.

Related Reports :

A. Hormone Replacement Therapy Market

https://www.industryarc.com/Report/15880/hormone-replacement-therapy-market.html

B. Isoflavones Market

https://www.industryarc.com/Report/16151/isoflavones-market.html

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.